Literature DB >> 2570283

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.

A M Gianni1, S Siena, M Bregni, C Tarella, A C Stern, A Pileri, G Bonadonna.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF), given to accelerate recovery from cytopenia induced by high-dose (7 g/m2) cyclophosphamide, reproducibly brought about a dramatic increase (up to 1000-fold) in the number of peripheral blood granulocyte-macrophage colony-forming units (CFU-GM). These circulating progenitors were harvested by leucapheresis and reinfused, together with autologous bone marrow cells, in seven patients with cancer after total body irradiation and melphalan. Complete haemopoietic recovery occurred in all seven transplanted patients in a very short time: mean (SD) 9.1 (0.9) days (range 8-11) to achieve more than 0.5 x 10(9)/l neutrophils, 9.9 (1.7) days (range 8-13) to over 1 x 10(9)/l neutrophils, 10.7 (2.6) days (range 9-16) to over 0.5 x 10(11)/l platelets, and 13.6 (4.2) days (range 13-21) to over 1.0 x 10(11)/l platelets. A reduction in the severity of mucositis was also observed. The rapid haematological recovery made possible by this approach promises to increase the therapeutic index of high-dose chemoradiotherapy regimens and to widen their role as treatment for chemoradiosensitive tumours.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570283     DOI: 10.1016/s0140-6736(89)90711-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  68 in total

1.  Long-term survival and late-onset complications of cancer patients treated with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.

Authors:  K Kohda; S Sakamaki; T Matsunaga; T Kuga; A Fujimi; Y Konuma; T Kusakabe; K Kogawa; T Akiyama; K Koike; Y Hirayama; Y Sasagawa; S Nojiri; Y Hirata; T Nishisato; G Y Niitsu
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 2.  New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment.

Authors:  N Thatcher
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

3.  The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.

Authors:  Ajay K Gopal; Mehdi Karami; JoAl Mayor; Mylene Macebeo; Michael Linenberger; William I Bensinger; Leona Holmberg
Journal:  J Clin Apher       Date:  2012-02-02       Impact factor: 2.821

Review 4.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

Review 5.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

Review 6.  Transplantation of hematopoietic stem cells from the peripheral blood.

Authors:  Jan Jansen; Susan Hanks; James M Thompson; Michael J Dugan; Luke P Akard
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

7.  Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors.

Authors:  N M Sposi; L I Zon; A Carè; M Valtieri; U Testa; M Gabbianelli; G Mariani; L Bottero; C Mather; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

Review 8.  Hematopoietic cytokines.

Authors:  Donald Metcalf
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

Review 9.  Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results.

Authors:  E Liehl; J Hildebrandt; C Lam; P Mayer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

Review 10.  Use and toxicity of the colony-stimulating factors.

Authors:  J R Schriber; R S Negrin
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.